In order to address the unmet clinical need for more than 69 million people living with severe mental illnesses, Beckman Coulter has introduced antipsychotic medication testing

In order to address the unmet clinical need for more than 69 million people living with severe menta ...

Currently, Beckman Coulter''s portfolio of therapeutic drug testing is being developed with an innovative nanoparticle technology to assess blood levels of antipsychotic drugs prescribed for treatment of schizophrenia. These tests will be available to clinical professionals within the United States and Europe, as well as in pharmacies. According to Salamone, the testing will begin at night and last for ten days, depending on the severity of symptoms.

You may also like: